Tags

Type your tag names separated by a space and hit enter

The effect of donepezil therapy on health costs in a Medicare managed care plan.
Manag Care Interface 2002; 15(3):63-70MC

Abstract

The objective of this study was to estimate the ramifications of donepezil use on the health care costs of a large Medicare managed care plan. Patients with a diagnosis of Alzheimer's disease or related dementia were identified from the claims-and-encounter records of the plan. Costs for 204 patients identified as having Alzheimer's disease and who were receiving donepezil were compared with a control group of 204 patients with Alzheimer's disease who had matching characteristics, but who were not receiving therapy. After controlling for age, gender, pharmacy benefits, comorbid conditions, and complications of dementia, annual costs for medical services and prescription drugs were found to be $3,891 lower for the study group. Costs were $4,192 lower for patients receiving longer-term therapy (> or = 270 day supply of donepezil) and $3,579 lower for patients receiving shorter-term therapy when compared with controls. By improving cognitive and daily functioning, donepezil may lower costs by improving medical management.

Authors+Show Affiliations

Institute for the Study for Aging, New York City, USA. jhill@rslmgmt.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Studies
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11925682

Citation

Hill, Jerrold W., et al. "The Effect of Donepezil Therapy On Health Costs in a Medicare Managed Care Plan." Managed Care Interface, vol. 15, no. 3, 2002, pp. 63-70.
Hill JW, Futterman R, Mastey V, et al. The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface. 2002;15(3):63-70.
Hill, J. W., Futterman, R., Mastey, V., & Fillit, H. (2002). The effect of donepezil therapy on health costs in a Medicare managed care plan. Managed Care Interface, 15(3), pp. 63-70.
Hill JW, et al. The Effect of Donepezil Therapy On Health Costs in a Medicare Managed Care Plan. Manag Care Interface. 2002;15(3):63-70. PubMed PMID: 11925682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of donepezil therapy on health costs in a Medicare managed care plan. AU - Hill,Jerrold W, AU - Futterman,Robert, AU - Mastey,Vera, AU - Fillit,Howard, PY - 2002/4/3/pubmed PY - 2002/4/23/medline PY - 2002/4/3/entrez SP - 63 EP - 70 JF - Managed care interface JO - Manag Care Interface VL - 15 IS - 3 N2 - The objective of this study was to estimate the ramifications of donepezil use on the health care costs of a large Medicare managed care plan. Patients with a diagnosis of Alzheimer's disease or related dementia were identified from the claims-and-encounter records of the plan. Costs for 204 patients identified as having Alzheimer's disease and who were receiving donepezil were compared with a control group of 204 patients with Alzheimer's disease who had matching characteristics, but who were not receiving therapy. After controlling for age, gender, pharmacy benefits, comorbid conditions, and complications of dementia, annual costs for medical services and prescription drugs were found to be $3,891 lower for the study group. Costs were $4,192 lower for patients receiving longer-term therapy (> or = 270 day supply of donepezil) and $3,579 lower for patients receiving shorter-term therapy when compared with controls. By improving cognitive and daily functioning, donepezil may lower costs by improving medical management. SN - 1096-5645 UR - https://www.unboundmedicine.com/medline/citation/11925682/The_effect_of_donepezil_therapy_on_health_costs_in_a_Medicare_managed_care_plan_ L2 - https://medlineplus.gov/managedcare.html DB - PRIME DP - Unbound Medicine ER -